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Abstract
Lantharenol® is a feed additive consisting of lanthanum carbonate octahydrate. It is currently
authorised as a zootechnical additive (decrease in phosphorous excretion via urine) for cats; this
opinion concerns the renewal of the authorisation. In 2007, the EFSA Panel on Additives and Products
or Substances used in Animal Feed (FEEDAP) adopted an opinion on the safety and efﬁcacy of
Lantharenol® as a feed additive for cats. The applicant has provided data demonstrating that the
additive complies with the conditions of authorisation. The available evidence, including the results of
the post-market monitoring plan, conﬁrms that the use of Lantharenol® in cat food at the maximum
authorised concentration of 7.5 g/kg of complete feed is safe for cats. In the absence of new data, the
FEEDAP Panel reiterates its previous conclusion that Lantharenol® does not pose a risk by inhalation
and is not an irritant to skin or eye and not a dermal sensitiser. The FEEDAP Panel considers that there
is no need for a continuation of a speciﬁc post-market monitoring plan.
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1. Introduction
1.1. Background and Terms of Reference
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. In particular, Article 14(1) of that Regulation lays down that an
application for renewal shall be sent to the Commission at the latest one year before the expiry date of
the authorisation.
The European Commission received a request from Bayer Healthcare AG2 for renewal of the
authorisation of Lantharenol® (lanthanum carbonate octahydrate), when used as a feed additive for
cats (category: ‘zootechnical additive’, functional group: ‘other zootechnical additives’).
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the
application to the European Food Safety Authority (EFSA) as an application under Article 14(1)
(renewal of the authorisation). The particulars and documents in support of the application were
considered valid by EFSA as of 11 April 2017.
According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and
documents submitted by the applicant, shall undertake an assessment in order to determine whether
the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on
the safety for the target animals, consumer, user and the environment and on the efﬁcacy of
Lantharenol® (lanthanum carbonate octahydrate), when used under the proposed conditions of use
(see Section 3.1.3).
1.2. Interpretation of the Terms of Reference
The application for renewal of the authorisation does not include a proposal for amending or
supplementing the conditions of the original authorisation that would have an impact on the efﬁcacy of
the additive; therefore, efﬁcacy is not assessed. The present opinion will focus only on the safety
aspects.
1.3. Additional information
The FEEDAP Panel adopted in 2007 an opinion on the safety and efﬁcacy of this product as a
zootechnical additive for cats (EFSA, 2007).
The additive (lanthanum carbonate octahydrate, Lantharenol®) is authorised for cats.3
2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier4 in support of the authorisation request for the use of Lantharenol® (lanthanum carbonate
octahydrate) as a feed additive. The technical dossier was prepared following the provisions of Article
14 of Regulation (EC) No 1831/2003, Regulation (EC) No 429/20085 and the applicable EFSA guidance
documents.
The FEEDAP Panel used the data provided by the applicant together with data from other sources,
such as previous risk assessments by EFSA or other expert bodies, peer-reviewed scientiﬁc papers and
other scientiﬁc reports to deliver the present output.
The European Union Reference Laboratory (EURL) considered that the conclusions and
recommendations reached in the previous assessment are valid and applicable for the current
application.6
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 Bayer HealthCare AG Animal Health Division 51368 Leverkusen Germany.
3 Commission Regulation (EC) No 163/2008 of 22 February 2008 concerning an authorisation of the preparation Lanthanum
carbonate octahydrate (Lantharenol) as a feed additive. OJ L 50, 23.2.2008, p. 3.
4 FEED dossier reference: FAD-2017-0013.
5 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
6 The full report is available on the EURL website: https://ec.europa.eu/jrc/sites/jrcsh/files/FinRep-FAD-2011-0021.pdf
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2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety of Lantharenol® (lanthanum
carbonate octahydrate) is in line with the principles laid down in Regulation (EC) No 429/2008 and the
Guidance on the renewal of the authorisation of feed additives (EFSA FEEDAP Panel, 2013).
3. Assessment
This assessment regards the renewal of the authorisation of the product Lantharenol® (≥ 85%
lanthanum carbonate octahydrate) as a zootechnical additive, functional group ‘other zootechnical
additives’, to be used in feedingstuffs for cats at the minimum and maximum content of 1,500 and
7,000 mg/kg complete feed, respectively. The speciﬁc intended effect under the authorisation granted
is: ‘decrease in phosphorous excretion via urine’.
3.1. Characterisation
3.1.1. Characterisation of the additive
The additive Lantharenol® contains lanthanum carbonate octahydrate (Chemical Abstracts Service
(CAS) No 6487394, molecular formula La2(CO3)3•8H2O and molecular weight 601.9 Da) as the
active substance.
The applicant stated that no changes have been introduced in the manufacturing process of the
additive since the original authorisation.
The applicant declared that the additive contains ≥ 85% of lanthanum carbonate octahydrate, with
the remainder being loosely bound water. The speciﬁcations of the additive, regarding the content of
the main constituents are: lanthanum 43–49%, carbonate 27–33% and ash 44–58%. The analysis of
three batches of the additive showed that Lantharenol® meets those speciﬁcations: lanthanum 45%,
carbonate 31.3% (range 31–32%) and ash 48.3% (range 48–49%). Analysis of heavy metals and
other impurities in the same batches also met the speciﬁcations (all results in mg/kg): ﬂuoride 22.6
(range 22–23); arsenic < 2; cadmium < 1; chromium < 2; lead < 1; mercury < 0.2.8,9 Analysis of
dioxins in three other batches of Lantharenol® showed an average content of 0.585 ng WHO-PCDD/
F-TEQ/kg additive (range: 0.576–0.600).10
The applicant also conducted analysis of Lantharenol® for microbiological contamination (total
aerobic count, yeasts and moulds and Escherichia coli) in three batches of the additive. Lanthanum
carbonate octahydrate is an inorganic material and is not expected to support microbiological growth.
The results of the analysis conﬁrmed this expectation.
It is noted that the analyses were performed on batches of the additive older than one year from
the date of the submission of the current application (analyses dated of 2014)11; the applicant
explained that fresh batches were not available for analysis because the additive is not currently being
manufactured or marketed.12
The additive Lantharenol® (lanthanum carbonate octahydrate) is a white crystalline powder. The
applicant submitted the same analysis for particle size distribution and dusting potential already
provided in the precedent dossier.13,14 These data were evaluated and reported in the earlier FEEDAP
Panel opinion on Lantharenol® for cats (EFSA, 2007).
8 Technical Dossier/Section II/Annex II_2.
9 The applicant clariﬁed that the symbol ‘<’ in all cases indicates that the ﬁndings were below the speciﬁcation limit; however, in
the view of the FEEDAP Panel, uncertainty remains regarding the LOQ/LOD of the analytical method. Technical Dossier/
Supplementary Information.
10 Technical Dossier/Section II/Annex II_13.
11 The FEEDAP Guidance for the renewal of authorisations states that: ‘Recent (not older than one year from the date of
submission of the application) analytical data from at least three batches for the composition of the additive and for the purity
should be provided’.
12 Technical Dossier/Supplementary Information/Annex 1.
13 Technical Dossier/Section II/Annex II_12.
14 Technical Dossier/Section II/Annex II_16–17.
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3.1.2. Stability and homogeneity
In the current application, the applicant provided data already submitted in the previous application
– which will not be re-assessed in the current scientiﬁc opinion – and additional studies aiming to
support the stability of the additive in premixtures.
3.1.3. Conditions of use
Lantharenol® is a feed additive that acts as an intestinal phosphate binder in cats. The duration of
administration is continuous. Lantharenol® should be incorporated into cat feed to achieve a
concentration of 1.5–7.5 g/kg of complete feed.
The current authorising Regulation indicates under Other provisions that:
• the additive is for use in adult cats,
• the recommended dose of inclusion in moist feed with 20–25% dry matter content is 340–
2,100 mg/kg and
• the simultaneous use of Lantharenol® with high phosphorus feeds should be avoided.
3.2. Safety
Since the use of the additive is only for cats, safety for consumers and the environment is out of
the scope of this scientiﬁc opinion. Therefore, the safety evaluation considers only the safety for cats
and the safety for the users.
The applicant performed a literature search in order to provide evidence that in the light of the
current knowledge the additive remains safe for cats and users under the approved conditions of
use.16 The scientiﬁc databases consulted were PubMed, Science Direct and Google Scholar; the search
period covered from January 2008 to October 2017. The keywords used were: ‘Lantharenol cat’,
‘Lantharenol human patient’, ‘Lantharenol user’, ‘Lantharenol environment’, ‘Lantharenol safety’,
‘Lantharenol safety cat’, ‘Lantharenol safety environment’ and ‘Renalzin’. A total of 444 scientiﬁc papers
were retrieved. Only four of the articles were considered potentially relevant, all related to the safety
of Lantharenol for cats.
The FEEDAP Panel notes that the search made by the applicant considered only the trade name of
the additive and not the chemical name of the active substance.
3.2.1. Safety for the target species
In the previous opinion on Lantharenol®, the FEEDAP Panel reported that ‘Based on the data from
the two tolerance studies provided in which no negative effects were seen after supplementing the
diet with at least a 10x overdose, the FEEDAP Panel concludes that Lantharenol® is safe for cats under
the conditions of use proposed’ (EFSA, 2007).
To support the safety of the additive for the target species, the applicant has provided new data in
the form of results of the post-market monitoring (PMM) plan foreseen in the authorisation and the
outcome of a literature search.
3.2.1.1. Results of the post-market monitoring plan
In its previous assessment, the FEEDAP Panel recommended a PMM plan for Lantharenol® (EFSA,
2007). This monitoring aimed to examine any consequence of the chronic exposure of cats to the
additive. A PMM plan was subsequently imposed in the authorising Regulation. The results of the PMM
have been submitted in the current dossier and summarised below.
The Marketing Authorisation Holder (MAH) has performed continuous PMM, pharmacovigilance and
evaluations of the beneﬁt–risk balance of RenalzinTM, a complementary feed for particular nutritional
16 Technical Dossier/Supplementary Information.
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purposes, containing Lantharenol® at 14% w/w. Lantharenol® was ﬁrst placed on the European Union
(EU) market in October 2008. The FEEDAP Panel agrees that the PMM data on RenalzinTM are relevant
to Lantharenol®. Two Global Periodic Safety Update Report (PSURs) were prepared by the MAH
covering the following periods: 12/9/2008 to 30/9/2009 (PSUR1)17 and 1/10/2009 to 31/5/2012
(PSUR2).18 The line listings for adverse events reported after the Data Lock Point of the last PSUR19
which covered the period 1/6/2012 to 31/12/2016 were also included in the technical dossier. The
reports covered the monitoring of the product not only in the countries of the European Economic area
but also in non-EEA and worldwide. Furthermore, they covered also incidences in non-target species as
well as off-label use of the product.
In total, there were 29 non-serious adverse events and 9 serious adverse events reported since the
authorisation was granted, taking into account both on-label and off-label uses in target species.
Considering the volume of RenalzinTM sold and the estimated number of treatments administered, the
incidence of adverse events reported in the target species was 0.0003% each for the periods covered
by PSUR1 and PSUR2. Thus, the worldwide incidence of adverse events following the use of RenalzinTM
in cats is low.
The most frequently affected system organ class reported in the target species was digestive tract
disorder, with the reported effects including inappetence, diarrhoea and vomiting. Non-speciﬁc
systemic disorders were also reported (exicosis, dehydration, depression, fever). The next most
common organ systems affected were the cardiovascular and respiratory systems. Neurological
disorders (nystagmus and circling) in connection with hypersalivation were reported in one other cat.
However, as the reported signs were nearly all common non-speciﬁc events, and in cats suffering from
renal disease, a product–disorder relationship was unclassiﬁable in the majority of cases. For all cases
of death and euthanasia (8 cats in total worldwide; occurred only in the period covered by PSUR2, a
product–disorder relationship was described by the MAH as unclassiﬁable or unlikely.
The incidence of adverse events (including decreased intake of water for drinking and vomiting in
dogs) reported in non-target species since the authorisation was granted was also low: three non-
serious and one serious, involving four animals in total, thus indicating that adverse effects were rare.
In the context of the PMM, the MAH conducted literature reviews quarterly since when
Lantharenol® was ﬁrst authorised.16 The applicant provided the list of search terms used in these
literature searches.20 The literature search found no reports indicating safety concerns to the target
species or the user following the use of Lantharenol®.
3.2.1.2. Results of the literature search
From the literature search performed (see also paragraph under Section 3.2), only four scientiﬁc
papers were chosen as being potentially relevant to the safety assessment. The FEEDAP
Panel considered these four papers and found that one of them (Schmidt et al., 2012) – in an
unpublished form – had been already assessed in the previous application. The other three papers
(DiBartola, 2010; Thom et al., 2013; Bernachon et al., 2014) did not provide any relevant additional
information on the safety of the product when used for cats. Consequently, there is no new
information available that would require the FEEDAP Panel to change its conclusions on target animal
safety made in the previous Opinion on Lantharenol (EFSA, 2007).
3.2.1.3. Conclusions on safety for the target species
The available evidence, based on the results of an extensive PMM showing a very low rate of
reported adverse effects in cats and on the outcome of a limited literature search, allowed the FEEDAP
Panel to conﬁrm that the use of Lantharenol® in cat food at the maximum authorised concentration of
7.5 g/kg of complete feed is safe for the target animals.
17 Technical Dossier/Section III/Annex_III_1.
18 Technical Dossier/Section III/Annex_III_2.
19 Technical Dossier/Section III/Annex_III_3.
20 Lantharenol® was used as a keyword in the search along with: Abuse, Adverse Drug Reaction, Adverse Effect, Adverse Event,
Adverse Experience, Adverse Reaction, Carcinogen, Cytotoxicity, Drug Interaction, Drug Safety, Efﬁcacy, Environment, Extra-
Label Use, Fatal Outcome, Interaction, Intoxication, Lactation Maximum Residue Limit, Mic, Minimal Inhibitory Limit, Misuse,
MRL, Mutagen, Off-Label Use, Overdose, Pharmacodynamics, Pharmacokinetic, Pharmacology, Pharmacovigilance, Poison,
Pregnant, Residue, Resistant, Safety, Side Effect, Suicide, Teratogen, Tolerance, Toxicity, Transmission Of Infectious Agent,
Unlicensed Use, Withdrawal Period.
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3.2.2. Safety for the user
The previous opinion on Lantharenol® reported that ‘Although the inhalation exposure did lead to
some persistent effects in the lung of exposed rats which was not fully explained, the dusting studies
indicate that user exposure via this route will not occur to any signiﬁcant extent. The substance is not
an irritant to skin or eye and is not a dermal sensitizer, is negative in genotoxicity tests and shows no
evidence of systemic effects in a 90-day study. On the basis of all this information, there is no
indication for any speciﬁc protective measures for handling this product either in a domestic or
commercial environment’ (EFSA, 2007).
Even if not speciﬁcally required in the PMM, the applicant also monitored the possible adverse
effects of the use of the product in humans (in the context of user safety). No reported adverse
effects in humans were collected in the period from 12/9/2008 to 31/12/2016.
In the absence of any new information, the FEEDAP Panel reiterates its previous conclusion on the
safety for the users.
3.3. Post-market monitoring
In the light of the results obtained from the PMM during the 10-year post-authorisation period, the
FEEDAP Panel considers that there is no need for a continuation of a speciﬁc PMM plan.
4. Conclusions
The applicant has provided data demonstrating that the additive complies with the conditions of
authorisation.
The available evidence, including the results of the PMM plan, conﬁrms that the use of
Lantharenol® in cat food at the maximum authorised concentration of 7.5 g/kg of complete feed is
safe for cats.
The FEEDAP Panel reiterates its previous conclusion that Lantharenol® does not pose a risk by
inhalation and is not an irritant to skin or eye and not a dermal sensitiser.
The FEEDAP Panel considers that there is no need for a continuation of a speciﬁc PMM plan.
Documentation provided to EFSA
1) Lantharenol® Feed Additive containing lanthanum carbonate octahydrate. February 2017.
Submitted by Bayer HealthCare AG Animal Health Division Germany.
2) Lantharenol® Feed Additive containing lanthanum carbonate octahydrate. Supplementary
information. October 2017. Submitted by Bayer HealthCare AG Animal Health Division
Germany.
3) Comments from Member States.
Chronology
Date Event
7/3/2017 Dossier received by EFSA
12/4/2017 Reception mandate from the European Commission
6/6/2017 Application validated by EFSA – Start of the scientiﬁc assessment
13/7/2017 Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation
(EC) No 1831/2003 – Scientiﬁc assessment suspended. Issues: characterisation, safety
6/9/2017 Comments received from Member States
10/10/2017 Reception of supplementary information from the applicant - Scientiﬁc assessment re-started
29/11/2018 Opinion adopted by the FEEDAP Panel. End of the Scientiﬁc assessment
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